Elena Yu. Osipova

Elena Yu. Osipova

Auto-generated profile, based on publicly available information

Elena Yu. Osipova

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
ATAleksei Titov
Aleksei Titov
RSRegina Shaykhutdinova
Regina Shaykhutdinova
OSOlga V. Shcherbakova
Olga V. Shcherbakova
YSYana V. Serdyuk
Yana V. Serdyuk
SSSavely A. Sheetikov
Savely A. Sheetikov
GEGrigory A. Efimov
Grigory A. Efimov
The ongoing COVID-19 pandemic calls for more effective diagnostic tools. T cell response assessment serves as an independent indicator of prior COVID-19 exposure while also contributing to a more comprehensive characterization of SARS-CoV-2 immunity. In this study, we systematically assessed the immunogenicity of 118 epitopes with immune cells collected from multiple cohorts of vaccinated, convalescent, healthy unexposed, and SARS-CoV-2–exposed donors. We identified 75 immunogenic epitopes, 24 of which were immunodominant. We further confirmed HLA restriction for 49 epitopes and described association with more than 1 HLA allele for 14 of these. Exclusion of 2 cross-reactive epitopes that generated a response in prepandemic samples left us with a 73-epitope set that offered excellent diagnostic specificity without losing sensitivity compared with full-length antigens, and this evoked a robust cross-reactive response. We subsequently incorporated this set of epitopes into an in vitro diagnostic Corona-T-test, which achieved a diagnostic accuracy of 95% in a clinical trial. In a cohort of asymptomatic seronegative individuals with a history of prolonged SARS-CoV-2 exposure, we observed a complete absence of T cell response to our epitope panel. In combination with strong reactivity to full-length antigens, this suggests that a cross-reactive response might protect these individuals.

23 September 2018 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
YBY. M. Bayzanova
Y. M. Bayzanova
NSN. N. Starostin
N. N. Starostin
IKI. B. Kumukova
I. B. Kumukova
EOE. Yu. Osipova
E. Yu. Osipova
PTPavel Trakhtman
Pavel Trakhtman
ЯБЯ. М. Байзянова
Я. М. Байзянова
Сравнительная характеристика способности лимфоцитов к пролиферации и их жизнеспособность в цельной донорской крови, обработанной гамма-излучением и методом патогенредукции с применением рибофлавина и ультрафиолета

13 December 2021 in medRxiv
Verified
Preprint
Open access
PDF file
ATAleksei Titov
Aleksei Titov
RSRegina Shaykhutdinova
Regina Shaykhutdinova
OSOlga V. Shcherbakova
Olga V. Shcherbakova
YSYana Serdyuk
Yana Serdyuk
SSSavely A. Sheetikov
Savely A. Sheetikov
GEGrigory A. Efimov
Grigory A. Efimov
The ongoing COVID-19 pandemic calls for more effective diagnostic tools, and T cell response assessment can serve as an independent indicator of prior COVID-19 exposure while also contributing to a more comprehensive characterization of SARS-CoV-2 immunity. In this study, we systematically assessed the immunogenicity of 118 epitopes with immune cells collected from multiple cohorts of vaccinated, convalescent, and healthy unexposed and SARS-CoV-2 exposed donors. We identified seventy-five immunogenic epitopes, 24 of which were immunodominant. We further confirmed HLA restriction for 49 epitopes, and described association with more than one HLA allele for 14 of these. After excluding two cross-reactive epitopes that generated a response in pre-pandemic samples, we were left with a 73-epitope set that offers excellent diagnostic specificity without losing sensitivity compared to full-length antigens, which evoked a robust cross-reactive response. We subsequently incorporated this set of epitopes into an in vitro diagnostic ‘Corona-T-test’ which achieved a diagnostic accuracy of 95% in a clinical trial. When applied to a cohort of asymptomatic seronegative individuals with a history of prolonged SARS-CoV-2 exposure, this test revealed a lack of specific T cell response combined with strong cross-reactivity to full-length antigens, indicating that abortive infection had occurred in these individuals.

1 January 2018 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
SBS.L. Blagov
S.L. Blagov
LSL.N. Shelikhova
L.N. Shelikhova
EOE.Y. Osipova
E.Y. Osipova
VKViktoriia Kiseleva
Viktoriia Kiseleva
AKA.S. Kazachenok
A.S. Kazachenok
MMMichael Maschan
Michael Maschan

20 August 2024 in eJHaem
Verified
Journal Article
Open access
AIAlbert Itov
Albert Itov
KIKarina Ilyasova
Karina Ilyasova
OSOlga Soldatkina
Olga Soldatkina
AKAnna Kazakova
Anna Kazakova
VKVladimir Kozeev
Vladimir Kozeev
YOYulia Olshanskaya
Yulia Olshanskaya
Pediatric low‐hypodiploidy B‐cell acute lymphoblastic leukemia (LH‐ALL) with TP53 variants has been proposed to be considered a manifestation of Li‐Fraumeni syndrome (LFS). However, our study demonstrates that of the majority the pathogenic variants in the TP53 gene are somatic (70.5%), and only 12.5% of patients with germline fulfilled the criteria of LFS. We also describe the first case of hypodiploid BCP‐ALL with a mosaic pathogenic mutation in TP53 and the first case of the persistence of clonal hematopoiesis with the TР53 gene mutation in the child during 3‐year minimal residual disease‐negative remission, similar to what has been described in adults.

12 August 2019 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
YNYu.A. Nikolaeva
Yu.A. Nikolaeva
ESE.V. Skorobogatova
E.V. Skorobogatova
KKKirill Kirgizov
Kirill Kirgizov
OHOncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology
Oncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology
EPE.A. Pristanskova
E.A. Pristanskova
NSN.V. Sidorova
N.V. Sidorova
Облако Mail.Ru - это ваше персональное надежное хранилище в интернете. Все нужные файлы всегда под рукой, доступны в любой точке мира с компьютера или смартфона.